Identification of Neuropsychiatric Copy Number Variants in a Health Care System Population

This cohort study evaluates the suitability of including pathogenic copy number variants associated with neuropsychiatric disorders in population screening by determining their prevalence and penetrance and exploring the personal utility of disclosing results.

[1]  D. Ledbetter,et al.  Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders , 2019, Nature Communications.

[2]  L. Schieve,et al.  Prevalence and Trends of Developmental Disabilities among Children in the United States: 2009–2017 , 2019, Pediatrics.

[3]  S. Banka,et al.  Presence of pathogenic copy number variants (CNVs) is correlated with socioeconomic status , 2019, Journal of Medical Genetics.

[4]  S. Scherer,et al.  Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders , 2019, Genetics in Medicine.

[5]  G. Kirov,et al.  Association of Rare Copy Number Variants With Risk of Depression , 2019, JAMA psychiatry.

[6]  J. McNeil,et al.  Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis , 2019, Genetics in Medicine.

[7]  Jason E. Miller,et al.  Human-Disease Phenotype Map Derived from PheWAS across 38,682 Individuals , 2018, American journal of human genetics.

[8]  Trygve E Bakken,et al.  Neurodevelopmental disease genes implicated by de novo mutation and copy number variation morbidity , 2018, Nature Genetics.

[9]  Alison B. Hamilton,et al.  A logic model for precision medicine implementation informed by stakeholder views and implementation science , 2018, Genetics in Medicine.

[10]  Jonathan P. Beauchamp,et al.  Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals , 2018, Nature Genetics.

[11]  Zornitza Stark,et al.  Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases , 2018, npj Genomic Medicine.

[12]  Marc S. Williams,et al.  Patient-Centered Precision Health In A Learning Health Care System: Geisinger's Genomic Medicine Experience. , 2018, Health affairs.

[13]  Caroline F. Wright,et al.  Common genetic variants contribute to risk of rare severe neurodevelopmental disorders , 2018, Nature.

[14]  G. Kirov,et al.  Medical consequences of pathogenic CNVs in adults: analysis of the UK Biobank , 2018, Journal of Medical Genetics.

[15]  R. Green,et al.  Patient understanding of, satisfaction with, and perceived utility of whole genome sequencing: Findings from the MedSeq Project , 2017, Genetics in Medicine.

[16]  Matthew S. Lebo,et al.  Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants , 2017, Genetics in Medicine.

[17]  P. Sullivan,et al.  Improved Ethical Guidance for the Return of Results from Psychiatric Genomics Research , 2017, Molecular Psychiatry.

[18]  D. Judge,et al.  Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. , 2018, Journal of cardiac failure.

[19]  S. Timmermans,et al.  The Actionability of Exome sequencing testing results. , 2017, Sociology of health & illness.

[20]  Alexander E. Lopez,et al.  Profiling and leveraging relatedness in a precision medicine cohort of 92,455 exomes , 2017, bioRxiv.

[21]  M. Owen,et al.  Schizophrenia and the neurodevelopmental continuum:evidence from genomics , 2017, World psychiatry : official journal of the World Psychiatric Association.

[22]  H. Ullum,et al.  Stakeholders in psychiatry and their attitudes toward receiving pertinent and incident findings in genomic research , 2017, American journal of medical genetics. Part A.

[23]  R. Nagy,et al.  Cancer Genetic Counseling and Testing in an Era of Rapid Change , 2017, Journal of Genetic Counseling.

[24]  T. Werge,et al.  Risk of Psychiatric Disorders Among Individuals With the 22q11.2 Deletion or Duplication: A Danish Nationwide, Register-Based Study , 2017, JAMA psychiatry.

[25]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[26]  Denise L. Perry,et al.  When bins blur: Patient perspectives on categories of results from clinical whole genome sequencing , 2017, AJOB empirical bioethics.

[27]  Donna M. Muzny,et al.  Resolution of Disease Phenotypes Resulting from Multilocus Genomic Variation , 2017, The New England journal of medicine.

[28]  Rolf Schröder,et al.  Clinical exome sequencing: results from 2819 samples reflecting 1000 families , 2016, European Journal of Human Genetics.

[29]  Matthew S. Lebo,et al.  The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult Patients: A Pilot Randomized Trial. , 2017, Annals of internal medicine.

[30]  L. Biesecker,et al.  Engagement and communication among participants in the ClinSeq Genomic Sequencing Study , 2016, Genetics in Medicine.

[31]  Marylyn D. Ritchie,et al.  Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.

[32]  W. Chung,et al.  Clinical application of whole-exome sequencing across clinical indications , 2015, Genetics in Medicine.

[33]  H. Mefford,et al.  Clinical phenotype of the recurrent 1q21.1 copy-number variant , 2015, Genetics in Medicine.

[34]  Evan E. Eichler,et al.  Molecular subtyping and improved treatment of neurodevelopmental disease , 2016, Genome Medicine.

[35]  Chunyu Liu,et al.  Genes with de novo mutations are shared by four neuropsychiatric disorders discovered from NPdenovo database , 2016, Molecular Psychiatry.

[36]  R. Kessler,et al.  Association of Mental Disorders With Subsequent Chronic Physical Conditions: World Mental Health Surveys From 17 Countries. , 2015, JAMA psychiatry.

[37]  G. Kirov,et al.  Erratum: Common alleles contribute to schizophrenia in CNV carriers , 2015, Molecular psychiatry.

[38]  D. Ledbetter,et al.  The Geisinger MyCode Community Health Initiative: an electronic health record-linked biobank for Precision Medicine research , 2015, Genetics in Medicine.

[39]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[40]  Frederick E. Dewey,et al.  CLAMMS: a scalable algorithm for calling common and rare copy number variants from exome sequencing data , 2015, Bioinform..

[41]  L. Biesecker,et al.  Participant use and communication of findings from exome sequencing: A mixed methods study , 2015, Genetics in Medicine.

[42]  D. Ledbetter,et al.  Shift happens: family background influences clinical variability in genetic neurodevelopmental disorders , 2015, Genetics in Medicine.

[43]  J. Rehm,et al.  Patients With High Mental Health Costs Incur Over 30 Percent More Costs Than Other High-Cost Patients. , 2016, Health affairs.

[44]  L. Vissers,et al.  Genetic studies in intellectual disability and related disorders , 2015, Nature Reviews Genetics.

[45]  R. Weksberg,et al.  Parents’ Experience with Pediatric Microarray: Transferrable Lessons in the Era of Genomic Counseling , 2016, Journal of Genetic Counseling.

[46]  Daniele Merico,et al.  Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome Sequencing in Children With Autism Spectrum Disorder. , 2015, JAMA.

[47]  J. Stoler,et al.  Clinical utility of a next generation sequencing panel assay for Marfan and Marfan‐like syndromes featuring aortopathy , 2015, American journal of medical genetics. Part A.

[48]  Xiang Li,et al.  Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions , 2014, Genetics in Medicine.

[49]  G. Kirov,et al.  CNVs in neuropsychiatric disorders. , 2015, Human molecular genetics.

[50]  Tom R. Gaunt,et al.  Copy number variations and cognitive phenotypes in unselected populations. , 2015, JAMA.

[51]  Jennifer B. McCormick,et al.  Public Perceptions of Disease Severity but Not Actionability Correlate with Interest in Receiving Genomic Results: Nonalignment with Current Trends in Practice , 2015, Public Health Genomics.

[52]  R. Green,et al.  'Someday it will be the norm': physician perspectives on the utility of genome sequencing for patient care in the MedSeq Project. , 2015, Personalized medicine.

[53]  Elhanan Borenstein,et al.  The discovery of integrated gene networks for autism and related disorders , 2015, Genome research.

[54]  Eric Vilain,et al.  Clinical exome sequencing for genetic identification of rare Mendelian disorders. , 2014, JAMA.

[55]  M. King,et al.  Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2 , 2014, Proceedings of the National Academy of Sciences.

[56]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[57]  A. Janssens,et al.  Personal utility in genomic testing: is there such a thing? , 2014, Journal of Medical Ethics.

[58]  V. Patel,et al.  The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013. , 2014, International journal of epidemiology.

[59]  A. McGuire,et al.  Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group , 2014, Genetics in Medicine.

[60]  M. Bellgrove,et al.  Neurodevelopmental and neuropsychiatric disorders represent an interconnected molecular system , 2014, Molecular Psychiatry.

[61]  Adam J. Schwarz,et al.  CNVs conferring risk of autism or schizophrenia affect cognition in controls , 2013, Nature.

[62]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[63]  R. Sharp,et al.  Genetics patients' perspectives on clinical genomic testing. , 2013, Personalized medicine.

[64]  David W. Evans,et al.  Developmental brain dysfunction: revival and expansion of old concepts based on new genetic evidence , 2013, The Lancet Neurology.

[65]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[66]  P. Elliott,et al.  UK Biobank: Current status and what it means for epidemiology , 2012 .

[67]  A. Bassett,et al.  Caregiver and adult patient perspectives on the importance of a diagnosis of 22q11.2 deletion syndrome. , 2012, Journal of intellectual disability research : JIDR.

[68]  E. Thorland,et al.  Towards an evidence‐based process for the clinical interpretation of copy number variation , 2012, Clinical genetics.

[69]  Marian Reiff,et al.  “What does it mean?”: Uncertainties in understanding results of chromosomal microarray testing , 2012, Genetics in Medicine.

[70]  A. StAteMent.  Points to consider in the clinical application of genomic sequencing , 2012, Genetics in Medicine.

[71]  J. Sebat,et al.  High Frequencies of De Novo CNVs in Bipolar Disorder and Schizophrenia , 2011, Neuron.

[72]  J. Buizer-Voskamp,et al.  Genome Arrays for the Detection of Copy Number Variations in Idiopathic Mental Retardation, Idiopathic Generalized Epilepsy and Neuropsychiatric Disorders: Lessons for Diagnostic Workflow and Research , 2011, Cytogenetic and Genome Research.

[73]  L. Koehly,et al.  Unpacking the Blockers: Understanding Perceptions and Social Constraints of Health Communication in Hereditary Breast Ovarian Cancer (HBOC) Susceptibility Families , 2011, Journal of Genetic Counseling.

[74]  Leslie G Biesecker,et al.  Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. , 2010, American journal of human genetics.

[75]  Joseph T. Glessner,et al.  PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. , 2007, Genome research.

[76]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.